Cognition Therapeutics CEO shares update on MAGNIFY Trial enrollment and the company’s work on dry AMD

News
Article

In a letter to shareholders, Ricciardi provided updates on Cognition’s 2024 pipeline and expected advances for several diseases.

©Cheangchai – stock.adobe.com

Image credit: ©Cheangchai – stock.adobe.com

In a letter to shareholders, Cognition Therapeutics Chief Executive Officer, Lisa Ricciardi shared an update on the company’s pipeline and strategy for the coming year.

According to the letter1 released in the first week of 2024, the Cognition anticipates proof-of-concept data from two Phase 2 neurodegenerative disease studies. The first being the company’s lead clinical oral product candidate, CT1812: the SHINE trial in mild-to-moderate Alzheimer's disease and the second being the SHIMMER trial in mild-to-moderate dementia with Lewy bodies (DLB). These two studies align with Cognition’s focus on the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina.

Regarding the company’s 2024 work on the treatment of dry age-related macular degeneration (AMD), Ricciardi’s letter1 shared that early proteomics analyses and subsequent preclinical work have provided compelling evidence that the sigma-2 receptor has an important role in the function of retinal pigment epithelial (RPE) cells, which are necessary for the preservation of vision. This research has opened the door for the company to expand into a fourth indication. They are actively enrolling participants in the 246-patient MAGNIFY trial for adults with dry AMD who have measurable geographic atrophy.

The company is working toward an effective, orally available treatment options that employ different modes of action which they believe would be well received in the medical and patient communities. Ricciardi also wrote in the letter1 the following, “for Cognition, expanding the pipeline for CT1812 to dry AMD has the potential to grow Cognition’s value across multiple age-related diseases. We look forward to a busy year in the vision space, working with retinal specialists to communicate the scientific rationale for using CT1812 in geographic atrophy and supporting enrollment of the Magnify trial.”

In the letter’s closing1, Ricciardi thank the patients, their families, and the investigators in these studies who propel the company forward.

Reference:
  1. Cognition Therapeutics CEO Issues Letter to Shareholders. Cognition Therapeutics. January 4, 2024. Accessed January 4, 2024. https://www.biospace.com/article/releases/cognition-therapeutics-ceo-issues-letter-to-shareholders/
Related Videos
Video 4 - "Treating Geographic Atrophy in Patients with Concurrent Neovascular AMD"
Video 3 - "Managing a Patient with Bilateral Geographic Atrophy"
Video 2 - "FDA-approved Therapies for Geographic Atrophy"
Video 1 - "Geographic Atrophy: Overview, Diagnosis, and Progression"
Marion Munk, MD, PhD, presenting slides
Marion Munk, MD, PhD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.